Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 8/20 | 0.71 |
| ▸ | PDE8A | O60658 | 9/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822875 | 0.88 | PDE8A (0.56) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL2060472 | 0.84 | PDE4A (0.67) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL7744345 | 0.83 | PDE8A (0.57) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL3919969 | 0.83 | YTHDC1 (0.70) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL27388531 | 0.83 | YTHDC1 (1.00) | YTHDC1ADORA2A | |
| SCHEMBL21076881 | 0.82 | TLR7 (0.61) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4172230 | 0.81 | PDE4A (0.64) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL2058782 | 0.80 | YTHDC1 (0.55) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12305259 | 0.80 | YTHDC1 (0.55) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL12305212 | 0.80 | YTHDC1 (0.55) | YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611268-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611268-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150239888-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239888-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| EP-2170888-B1 | PURINE DERIVATIVES AND THEIR USE AS MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8993755-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2015-03-31 | — | — | US | disclosed |
| US-8993755-B2 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2015-03-31 | — | — | US | disclosed |
| US-20140135492-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2014-05-15 | — | — | US | disclosed |
| US-20140135492-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. | 2014-05-15 | — | — | US | disclosed |
| US-20120244121-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244121-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110236348-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110236348-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7968544-B2 | Agonists; Treatment of Hepatitis C virus; purine derivatives | GILEAD SCIENCES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968544-B2 | Agonists; Treatment of Hepatitis C virus; purine derivatives | GILEAD SCIENCES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2009034386-A1 | DERIVATIVES OF ADENINE AND 8-AZA-ADENINE AND USES THEREOF-796 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2009-02-19 | — | — | US | disclosed |
| WO-2009005687-A1 | PURINE DERIVATIVES AND THEIR USE AS MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135492-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | YTHDC1 4748/4885PDE8A 657/4885PDE4A 1427/4885 |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | YTHDC1 4763/4885PDE8A 598/4885PDE4A 1386/4885 |
| US-20110236348-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | YTHDC1 4773/4885PDE8A 797/4885PDE4A 1018/4885 |
| US-20150239888-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | YTHDC1 4748/4885PDE8A 657/4885PDE4A 1427/4885 |
| US-20120244121-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | YTHDC1 4773/4885PDE8A 797/4885PDE4A 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.